These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 16445979)

  • 1. Successful treatment of primary refractory anemia with a combination regimen of all-trans retinoic acid, calcitriol, and androgen.
    Zhang W; Zhou F; Cao X; Cheng Y; He A; Liu J; Ma X; Chen G
    Leuk Res; 2006 Aug; 30(8):935-42. PubMed ID: 16445979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Retrospective observation of curative effects on MDS refractory anemia with combination of all-trans retinoic acid, 1, 25-dihydroxyvitamin D3 and androgen].
    Zhou FL; Zhang WG; Cao XM; Chen YX; He AL; Liu J; Zhao WH; Ma XR; Chen G
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):861-6. PubMed ID: 16277859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
    Guan M; Chen SC; Ge CW
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
    Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
    Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
    Morris MJ; Smaletz O; Solit D; Kelly WK; Slovin S; Flombaum C; Curley T; Delacruz A; Schwartz L; Fleisher M; Zhu A; Diani M; Fallon M; Scher HI
    Cancer; 2004 May; 100(9):1868-75. PubMed ID: 15112267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.
    Trump DL; Potter DM; Muindi J; Brufsky A; Johnson CS
    Cancer; 2006 May; 106(10):2136-42. PubMed ID: 16598750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Low dose all-trans retinoic acid and androgen therapy for patients with myelodysplastic syndrome].
    Guan M; Chen SC; Li RS; Ge CW; Zhu HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):774-8. PubMed ID: 15631659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
    Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
    Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
    Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.
    Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
    Br J Haematol; 2009 Feb; 144(3):342-9. PubMed ID: 19036104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
    Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
    Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Multiple discriminant analysis for prognosis of refractory anemia].
    Kobaba R; Kousaki M; Andou S; Okuda K; Tamura A; Miyazaki E; Inoue N; Okamoto T; Takemoto Y; Kanamaru A
    Rinsho Ketsueki; 1991 Aug; 32(8):815-21. PubMed ID: 1942520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prednisolone, 1 alpha hydroxyvitamin D3 and androgens in the management in patients with refractory anemias].
    Yoshida Y; Yamagishi M
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1178-82. PubMed ID: 2837980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
    Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
    Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients.
    Di Febo A; Laurenti L; Falcucci P; Tosti ME; Fianchi L; Pagano L; Leone G
    Am J Ther; 2007; 14(4):351-5. PubMed ID: 17667210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
    Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
    Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001).
    Hartmann JT; Mayer F; Schleicher J; Horger M; Huober J; Meisinger I; Pintoffl J; Käfer G; Kanz L; Grünwald V;
    Cancer; 2007 Aug; 110(4):861-6. PubMed ID: 17599772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens.
    Leleu X; Terriou L; Duhamel A; Moreau AS; Andrieux J; Dupire S; Coiteux V; Berthon C; Micol JB; Guieze R; Facon T; Bauters F
    Ann Hematol; 2006 Oct; 85(10):711-6. PubMed ID: 16830141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.